Nimodipine microparticles - Edge Therapeutics

Drug Profile

Nimodipine microparticles - Edge Therapeutics

Alternative Names: EG-1962; NimoVent; Polymeric nimodipine microparticle

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Edge Therapeutics
  • Class Antihypertensives; Dihydropyridines; Nicotinic-acids
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No
  • Available For Licensing Yes - Brain injuries; Cerebral ischaemia

Highest Development Phases

  • Phase III Cerebral ischaemia

Most Recent Events

  • 03 May 2017 Phase-III clinical trials in Cerebral ischaemia (Prevention) in Canada, Germany and Israel before May 2017 (Intraventricular) (NCT02790632)
  • 01 Nov 2016 Phase-I clinical trials in Cerebral ischaemia (Prevention) in USA (Intracisternal) (NCT02893826)
  • 06 Sep 2016 Pharmacokinetics data from the phase I/IIa trial in Cerebral ischaemia (Prevention) released by Edge Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top